Denali Advisors LLC Revance Therapeutics, Inc. Transaction History

Denali Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 21, 2023	SELL	$18.36 - $35.27 $22,032 - $42,324	-1,200 Reduced 52.17%	1,100 $35,000
Q4 2022 Feb 09, 2023	SELL	$18.32 - $30.66 $40,304 - $67,452	-2,200 Reduced 48.89%	2,300 $42,000
Q3 2022 Oct 25, 2022	SELL	$14.33 - $28.47 $14,330 - $28,470	-1,000 Reduced 18.18%	4,500 $122,000
Q2 2022 Jul 18, 2022	SELL	$11.52 - $20.4 $11,520 - $20,400	-1,000 Reduced 15.38%	5,500 $76,000
Q4 2021 Jan 21, 2022	BUY	$12.46 - $27.87 $80,990 - $181,155	6,500 New	6,500 $106,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Denali Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Denali Advisors LLC with notifications on news.